These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2702801)

  • 1. Influence of debrisoquin phenotype on the inducibility of propranolol metabolism.
    Shaheen O; Biollaz J; Koshakji RP; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1989 Apr; 45(4):439-43. PubMed ID: 2702801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
    Ward SA; Walle T; Walle UK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple pathways of propranolol's metabolism are inhibited by debrisoquin.
    Anthony L; Koshakji R; Wood AJ
    Clin Pharmacol Ther; 1989 Sep; 46(3):297-300. PubMed ID: 2776392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.
    Gross AS; Phillips AC; Rieutord A; Shenfield GM
    Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade.
    Raghuram TC; Koshakji RP; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1984 Jul; 36(1):51-6. PubMed ID: 6734049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.
    Mikus G; Gross AS; Beckmann J; Hertrampf R; Gundert-Remy U; Eichelbaum M
    Clin Pharmacol Ther; 1989 May; 45(5):562-7. PubMed ID: 2498026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
    Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective disposition of carvedilol is determined by CYP2D6.
    Zhou HH; Wood AJ
    Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.
    Anthony LB; Boeve TJ; Hande KR
    Cancer Chemother Pharmacol; 1995; 36(2):125-8. PubMed ID: 7767948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin.
    McGourty JC; Silas JH; Fleming JJ; McBurney A; Ward JW
    Clin Pharmacol Ther; 1985 Oct; 38(4):409-13. PubMed ID: 2864157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.
    Lennard MS; Tucker GT; Silas JH; Freestone S; Ramsay LE; Woods HF
    Clin Pharmacol Ther; 1983 Dec; 34(6):732-7. PubMed ID: 6641087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin.
    Roy SD; Hawes EM; McKay G; Korchinski ED; Midha KK
    Clin Pharmacol Ther; 1985 Aug; 38(2):128-33. PubMed ID: 4017414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil.
    Shaheen O; Patel J; Avant GR; Hamilton M; Wood AJ
    Clin Pharmacol Ther; 1986 Dec; 40(6):650-5. PubMed ID: 3780126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
    Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.
    Caraco Y; Sheller J; Wood AJ
    J Pharmacol Exp Ther; 1997 Apr; 281(1):330-6. PubMed ID: 9103514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.
    Sowinski KM; Burlew BS
    Pharmacotherapy; 1997; 17(6):1305-10. PubMed ID: 9399616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolism of glyburide in subjects of known debrisoquin phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Clin Pharmacol Ther; 1989 Mar; 45(3):277-84. PubMed ID: 2493353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
    Edeki TI; He H; Wood AJ
    JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.
    Lennard MS; Jackson PR; Freestone S; Ramsay LE; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):106S-107S. PubMed ID: 6146334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.